Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Neuro-oncology - 3 May 2024

Odia Yazmin, Hall Matthew D, Cloughesy Timothy Francis, Wen Patrick Y, Arrillaga-Romany Isabel, Daghistani Doured, Mehta Minesh P, Tarapore Rohinton S, Ramage Samuel C, Allen Joshua E

Abstract excerpt

BACKGROUND: Diffuse midline glioma, H3 K27-altered (H3 K27M-altered DMG) are invariably lethal, disproportionately affecting the young and without effective treatment besides radiotherapy. The 2016 World Health Organization (WHO) Central Nervous System (CNS) Tumors Classification defined H3 K27M mutations as pathognomonic but restricted diagnosis to diffuse gliomas involving midline structures by 2018....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Dopamine Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Imidazoles

Share to Neoplasm Recurrence, Local

Share to Pyridines

Share to Pyrimidines

Share to Receptors, Dopamine D2

Source

Open in PubMed Open full text

Identifiers

PMID: 38386699
DOI: 10.1093/neuonc/noae021
PMCID: PMC11066928

Genes

DRD2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.PMID 38386699Read ↗

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Semantic proximity Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.Semantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.Semantic proximity Read ↗

H3 K27M-mutant diffuse midline gliomas in different anatomical locations.Semantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.Semantic proximity Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

H3K27M mutant diffuse midline glioma: a case report.Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.